IL204804A - Purine history of pyrimidine is conserved - Google Patents

Purine history of pyrimidine is conserved

Info

Publication number
IL204804A
IL204804A IL204804A IL20480410A IL204804A IL 204804 A IL204804 A IL 204804A IL 204804 A IL204804 A IL 204804A IL 20480410 A IL20480410 A IL 20480410A IL 204804 A IL204804 A IL 204804A
Authority
IL
Israel
Prior art keywords
purine derivatives
substituted purine
pyrimidine substituted
pyrimidine
derivatives
Prior art date
Application number
IL204804A
Other languages
English (en)
Hebrew (he)
Other versions
IL204804A0 (en
Original Assignee
Verastem Inc
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc, S Bio Pte Ltd filed Critical Verastem Inc
Publication of IL204804A0 publication Critical patent/IL204804A0/en
Publication of IL204804A publication Critical patent/IL204804A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL204804A 2007-10-05 2010-03-28 Purine history of pyrimidine is conserved IL204804A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97772007P 2007-10-05 2007-10-05
US7553208P 2008-06-25 2008-06-25
PCT/SG2008/000379 WO2009045175A1 (fr) 2007-10-05 2008-10-03 Dérivés de purine substitués par pyrimidine

Publications (2)

Publication Number Publication Date
IL204804A0 IL204804A0 (en) 2010-11-30
IL204804A true IL204804A (en) 2014-11-30

Family

ID=40030252

Family Applications (2)

Application Number Title Priority Date Filing Date
IL204804A IL204804A (en) 2007-10-05 2010-03-28 Purine history of pyrimidine is conserved
IL235555A IL235555B (en) 2007-10-05 2014-11-06 Methods for preparing pyrimidine-converted purine derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL235555A IL235555B (en) 2007-10-05 2014-11-06 Methods for preparing pyrimidine-converted purine derivatives

Country Status (17)

Country Link
US (3) US8247410B2 (fr)
EP (1) EP2209786B1 (fr)
JP (2) JP5479346B2 (fr)
KR (3) KR20160116045A (fr)
CN (2) CN104119336B (fr)
AU (1) AU2008307798B2 (fr)
BR (1) BRPI0817503B8 (fr)
CA (1) CA2701581C (fr)
DK (1) DK2209786T3 (fr)
ES (1) ES2406129T3 (fr)
HK (2) HK1145832A1 (fr)
IL (2) IL204804A (fr)
MX (1) MX2010003668A (fr)
MY (1) MY150993A (fr)
RU (2) RU2518098C2 (fr)
WO (1) WO2009045175A1 (fr)
ZA (1) ZA201003118B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
BRPI0614184A8 (pt) 2005-07-25 2017-10-10 Aptevo Res & Development Llc Redução de células b com o uso de moléculas de ligação específicas para cd37 e específicas para cd20
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
EP2307414A4 (fr) * 2008-07-07 2011-10-26 Xcovery Holding Co Llc Inhibiteurs sélectifs des isoformes de la pi3 kinase
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
KR20110098908A (ko) * 2008-11-11 2011-09-02 엑스커버리 홀딩 컴퍼니 엘엘씨 ＰＩ3Ｋ/ｍＴＯＲ 키나제 억제제
CA2756067A1 (fr) 2009-03-27 2010-09-30 Pathway Therapeutics, Inc. Pyrimidinyl et 1,3,5-triazinyl benzimidazole sulfonamides et leur utilisation en therapie anticancereuse
WO2010114494A1 (fr) * 2009-04-03 2010-10-07 S*Bio Pte Ltd Purines 2-morpholino 8-substituées pour une utilisation en tant qu'inhibiteurs de pi3k et/ou mtor dans le traitement de troubles prolifératifs
CN102428085B (zh) 2009-04-03 2015-07-15 维拉斯通股份有限公司 作为激酶抑制剂的嘧啶取代的嘌呤化合物
AR080945A1 (es) 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011078795A1 (fr) * 2009-12-21 2011-06-30 S*Bio Pte Ltd Purines pontées à substitution morpholino
EP4438734A2 (fr) 2010-06-14 2024-10-02 The Scripps Research Institute Reprogrammation de cellules en un nouveau devenir
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
WO2012172043A1 (fr) 2011-06-15 2012-12-20 Laboratoire Biodim Dérivés de purine et leur utilisation comme produits pharmaceutiques pour prévenir ou traiter les infections bactériennes
BR112014013568A8 (pt) * 2011-12-05 2017-06-13 Novartis Ag anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
TW201410657A (zh) 2012-08-02 2014-03-16 Endo Pharmaceuticals Inc 經取代胺基－嘧啶衍生物
CN104557872B (zh) * 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
SG11201604595VA (en) * 2013-12-11 2016-07-28 Biogen Ma Inc Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016109426A1 (fr) * 2014-12-29 2016-07-07 Verastem, Inc. Régime posologique oral d'un double inhibiteur de mtor et pi3
CN105985354B (zh) * 2015-02-09 2020-10-02 南京盖特医药技术有限公司 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
TWI689508B (zh) 2015-03-30 2020-04-01 日商第一三共股份有限公司 可作爲ｐｉ３ｋ抑制劑之吡唑衍生物及其用途
KR101589900B1 (ko) 2015-07-30 2016-01-29 강영만 바닥설치용 경계구
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
WO2017210408A1 (fr) * 2016-06-02 2017-12-07 Celgene Corporation Agents anti-trypanosomes et anti-leishmania pour animaux et humains
EA037871B1 (ru) * 2016-06-16 2021-05-28 Янссен Фармацевтика Нв Производные азабензимидазола в качестве ингибиторов pi3k beta
KR102399639B1 (ko) 2016-12-02 2022-05-18 다이이찌 산쿄 가부시키가이샤 신규 엔도-β-N-아세틸글루코사미니다아제
AU2018244011A1 (en) * 2017-03-31 2019-11-07 Ftg Bio Llc Salt forms of amino pyrazine purine based selective kinase inhibitor
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
JP2020521739A (ja) 2017-05-23 2020-07-27 エムイーアイ ファーマ，インク． 併用療法
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
SG11202103118PA (en) * 2018-09-27 2021-04-29 Shanghai Yingli Pharmaceutical Co Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
MX2021007179A (es) * 2018-12-20 2021-09-28 Ksq Therapeutics Inc Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1).
EP4236958A4 (fr) 2020-10-30 2024-09-11 Ksq Therapeutics Inc Formes de pyrazolopyrimidines substituées à l'état solide et leurs utilisations
WO2024041519A1 (fr) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 Composé morpholinyl quinazoline, composition pharmaceutique et utilisation associée

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617304A (en) * 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
US4772606A (en) * 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
NZ502642A (en) 1997-07-03 2002-06-28 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
NZ506234A (en) * 1998-02-26 2003-05-30 Aventis Pharma Inc 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines, pharmaceuticals thereof and their use for inhibiting cdk-2
WO2001083456A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
MXPA03000525A (es) * 2000-07-19 2003-05-14 Novartis Ag Sales de valsartan.
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
AU2002342051B2 (en) 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
AU2003265636A1 (en) 2002-09-06 2004-03-29 Smithkline Beecham Corporation Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds
WO2004035740A2 (fr) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Nouveaux composes
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
SI2316831T1 (sl) * 2002-11-21 2013-07-31 Novartis Ag 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
EP1575940B1 (fr) * 2002-11-21 2011-10-05 Novartis AG Pyrimidines 2,4,6-trisubstitutees utilisees comme inhibiteurs de phosphotidylinositol (pi) 3-kinase et leur utilisation dans le traitement du cancer
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
EP1940843A4 (fr) 2005-08-11 2010-09-15 Ariad Pharma Inc Derives heterocycliques insatures
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
GB0519245D0 (en) 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
US20110009403A1 (en) * 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
CN104119336B (zh) 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
TW200938201A (en) 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
WO2009146406A1 (fr) * 2008-05-30 2009-12-03 Genentech, Inc. Composés inhibiteurs de la pi3k de type purine et procédés d'utilisation
EP2310391A1 (fr) * 2008-06-27 2011-04-20 S*BIO Pte Ltd Purines substituées par la pyrazine
EP2307414A4 (fr) 2008-07-07 2011-10-26 Xcovery Holding Co Llc Inhibiteurs sélectifs des isoformes de la pi3 kinase
WO2010114494A1 (fr) 2009-04-03 2010-10-07 S*Bio Pte Ltd Purines 2-morpholino 8-substituées pour une utilisation en tant qu'inhibiteurs de pi3k et/ou mtor dans le traitement de troubles prolifératifs
CN102428085B (zh) 2009-04-03 2015-07-15 维拉斯通股份有限公司 作为激酶抑制剂的嘧啶取代的嘌呤化合物

Also Published As

Publication number Publication date
IL235555A0 (en) 2014-12-31
AU2008307798A1 (en) 2009-04-09
DK2209786T3 (da) 2013-06-03
IL204804A0 (en) 2010-11-30
KR20150063171A (ko) 2015-06-08
HK1145832A1 (en) 2011-05-06
AU2008307798B2 (en) 2013-10-03
US20140066620A1 (en) 2014-03-06
EP2209786B1 (fr) 2013-02-27
CN101889015B (zh) 2014-06-04
JP5479346B2 (ja) 2014-04-23
CN104119336B (zh) 2016-08-24
RU2010117737A (ru) 2011-11-10
RU2518098C2 (ru) 2014-06-10
US8609838B2 (en) 2013-12-17
US20100298319A1 (en) 2010-11-25
KR101701109B1 (ko) 2017-02-13
KR101643237B1 (ko) 2016-07-27
CA2701581A1 (fr) 2009-04-09
RU2681081C2 (ru) 2019-03-04
BRPI0817503B8 (pt) 2021-05-25
IL235555B (en) 2019-08-29
RU2014110894A (ru) 2015-07-10
KR20100075609A (ko) 2010-07-02
ES2406129T3 (es) 2013-06-05
HK1203488A1 (en) 2015-10-30
CA2701581C (fr) 2016-12-20
CN101889015A (zh) 2010-11-17
CN104119336A (zh) 2014-10-29
KR20160116045A (ko) 2016-10-06
JP5885729B2 (ja) 2016-03-15
JP2014139159A (ja) 2014-07-31
BRPI0817503A2 (pt) 2015-05-05
EP2209786A1 (fr) 2010-07-28
JP2010540625A (ja) 2010-12-24
WO2009045175A1 (fr) 2009-04-09
MY150993A (en) 2014-03-31
US8247410B2 (en) 2012-08-21
US20130079512A1 (en) 2013-03-28
MX2010003668A (es) 2010-07-02
BRPI0817503B1 (pt) 2019-10-29
ZA201003118B (en) 2011-08-31

Similar Documents

Publication Publication Date Title
HK1203488A1 (en) Pyrimidine substituted purine derivatives
HRP20140377T1 (en) Pyrimidine derivatives
IL205425A0 (en) Novel pyrimidine derivatives
IL192610A0 (en) Pyrimidine derivatives
HRP20171398T1 (hr) Novi derivati adenina
GB0614579D0 (en) Pyrimidine derivatives
HK1220455A1 (zh) 嘧啶取代的大環抑制劑
IL210176A0 (en) Substituted pyrimidone derivatives
SI2125792T1 (sl) Purinski derivati kot imunomodulatorji
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
HK1120269A1 (en) Pyrimidine derivatives
ZA201003438B (en) Antiviral nucleoside compounds
ZA201006104B (en) Substituted xanthine derivatives
IL210172A0 (en) Substituted pyrimidin-4-one derivatives
EP2178375A4 (fr) Dérivés de la pyrazoloý1,5-a¨pyrimidine
GB0706632D0 (en) New purine derivatives
ZA201000107B (en) Pyrimidine derivatives 934
GB0525080D0 (en) Pyrimidine derivatives
IL195018A0 (en) Piperidinyl pyrimidine derivatives
GB0525083D0 (en) Pyrimidine derivatives
HK1215434A1 (zh) 取代的嘧啶衍生物
EP2061470A4 (fr) Dérivés de la pyrimidinone substitués par un halogénoalkyle
EP2094704A4 (fr) Dérivés de pyrimidinone substitués par cis-cyclohexyle
GB0525081D0 (en) Pyrimidine derivatives
ZA201102607B (en) Heterocyclic antiviral arylpyridone derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed